Guideline: Test can help make diagnosis of Creutzfeldt-Jakob disease

September 19, 2012

A new guideline released by the American Academy of Neurology may help doctors in making the diagnosis of Creutzfeldt-Jakob disease. The guideline is published in the September 19, 2012, online issue of Neurology.

Creutzfeldt-Jakob disease is a rare, always fatal brain disorder that involves quickly progressing dementia. New cases appear in about one person per million each year worldwide and confirming the is challenging. People with the disease can have a wide range of symptoms. Many other conditions can cause similar symptoms, and with some of these conditions the dementia can be treated.

The guideline focused only on the diagnosis of sporadic Creutzfeldt-Jakob disease.

While several tests are available to help diagnose sporadic Creutzfeldt-Jakob disease, a brain biopsy is the most accurate test that can be performed on a person living with the disease. Brain biopsy is potentially dangerous.

The guideline examined the of testing for a protein called 14-3-3 in the spinal fluid. The guideline authors reviewed all of the available evidence on the test, which included samples of 1,849 people with suspected sporadic Creutzfeldt-Jakob disease from nine studies.

They found that in cases where doctors strongly suspect Creutzfeldt-Jakob to be the cause of the dementia, the test can be helpful in reducing the of the diagnosis. However, the test is not accurate enough to diagnose the disease with certainty or to rule it out completely. The test has a sensitivity of about 92 percent and a specificity of about 80 percent. Sensitivity is the percentage of patients with the disease who have a positive test result, and specificity is the percentage of patients who do not have the disease and who are correctly identified as having a negative test result.

The guideline determined that the 14-3-3 protein test can be useful when the of the person having Creutzfeldt-Jakob disease is between 20 percent and 90 percent.

"This means that if the physician considers the likelihood of Creutzfeldt-Jakob disease to be extremely low or extremely high, then testing for 14-3-3 protein would not be useful regardless of the result," said guideline author Taim Muayqil, MBBS, FRCPC, of King Saud University in Riyadh, Saudi Arabia, and a member of the American Academy of Neurology.

Muayqil noted that only doctors experienced in diagnosing should determine whether the 14-3-3 test is needed and how results should be interpreted.

Explore further: Alzheimer's might be transmissible in similar way as infectious prion diseases: study

More information: www.aan.com/guidelines

Related Stories

Recommended for you

Neuroscientists illuminate role of autism-linked gene

May 25, 2016

A new study from MIT neuroscientists reveals that a gene mutation associated with autism plays a critical role in the formation and maturation of synapses—the connections that allow neurons to communicate with each other.

Teen brains facilitate recovery from traumatic memories

May 25, 2016

Unique connections in the adolescent brain make it possible to easily diminish fear memories and avoid anxiety later in life, according to a new study by Weill Cornell Medicine researchers. The findings may have important ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.